New pill targets Hard-to-Treat cancers in early trial

NCT ID NCT06004245

Recruiting now Disease control Sponsor: Vividion Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 38 times

Summary

This early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug works alone or combined with other treatments. About 280 participants will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Alfred Hospital
RECRUITING

Melbourne, Victoria, 3181, Australia
Asan Medical Center
ACTIVE_NOT_RECRUITING

Seoul, 05505, South Korea
BCCA-Vancouver Cancer Centre
COMPLETED

Vancouver, British Columbia, V5Z 4E6, Canada
CLCC Leon Berard Lyon
COMPLETED

Lyon, 69008, France
City of Hope Cancer Center
RECRUITING

Duarte, California, 91010, United States
City of Hope at Irvine Lennar
RECRUITING

Irvine, California, 91355, United States
Clinica Universidad de Navarra Madrid
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28027, Spain
Clinica Universitaria de Navarra
ACTIVE_NOT_RECRUITING

Pamplona, Navarre, 31008, Spain
Duke University
COMPLETED

Durham, North Carolina, 27705, United States
Emory University School of Medicine
RECRUITING

Atlanta, Georgia, 30322, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Gustave Roussy
ACTIVE_NOT_RECRUITING

Villejuif, 94805, France
Hospital Clinico Universitario de Valencia
ACTIVE_NOT_RECRUITING

Valencia, Valencia, 46010, Spain
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Norton Cancer Institute - MDC
RECRUITING

Louisville, Kentucky, 40202, United States
Oklahoma University Health Sciences Center
RECRUITING

Oklahoma City, Oklahoma, 73170, United States
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
Rigshospitalet
ACTIVE_NOT_RECRUITING

København Ø, 2100, Denmark
Royal Marsden Hospital (Sutton)
RECRUITING

Sutton, SM2 5PT, United Kingdom
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START Madrid. Centro Integral Oncologico Clara Campal
ACTIVE_NOT_RECRUITING

Madrid, Madrid, 28050, Spain
Sarah Cannon Research Institute
RECRUITING

London, W1G 6AD, United Kingdom
Sarawak Public Hospital
ACTIVE_NOT_RECRUITING

Kuching, Sarawak, 93586, Malaysia
Seoul National University Bundang Hospital
ACTIVE_NOT_RECRUITING

Seongnam-si, 13620, South Korea
Seoul National University Hospital
RECRUITING

Seoul, 03080, South Korea
St Vincents Sydney
RECRUITING

Darlinghurst, New South Wales, 2010, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Christie
ACTIVE_NOT_RECRUITING

Manchester, M20 4BX, United Kingdom
UZ Leuven Gasthuisberg
ACTIVE_NOT_RECRUITING

Leuven, 3000, Belgium
Vall d'Hebron Institute of Oncology (VHIO), Barcelona
ACTIVE_NOT_RECRUITING

Barcelona, BARCELONA, 08035, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS ADVANCED SOLID TUMORS COLORECTAL CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

COLORECTAL ADENOCARCINOMA